LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

LLY

817.59

-1.55%↓

UNH

566.44

+0.03%↑

JNJ

159.98

+0.01%↑

NVO

111.95

+0.05%↑

ABBV

203.23

-0.43%↓

Home・Listă Acțiuni・MacroGenics Inc

MacroGenics Inc

Închisă

Sector Sănătate

3.87 5.74

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

3.84

Maxim

3.93

Indicatori cheie
By Trading Economics
Venit	-3.5M -56M
Vânzări	49M 58M
EPS	-0.89
Marjă de profit	-96.273
Angajați	339
EBITDA	-49M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+84.5 upside

Dividende
By Dow Jones
Următoarele câștiguri	5 nov. 2024

Statistici piață
By TradingEconomics
Capitalizare de piață	3.8M 233M
Deschiderea anterioară	-1.87
Închiderea anterioară	3.87

Sentimentul știrilor

By Acuity

73%

27%

346 / 389 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

3.34 / 3.9 Suport & Rezistență

MacroGenics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

1 nov. 2024, 22:50 UTC

Acțiuni populare

Stocks to Watch: Nvidia, Intel, Sherwin-Williams, Dow, Nuwellis

1 nov. 2024, 22:43 UTC

Principalele dinamici ale pieței

Nvidia, Sherwin-Williams Shares Up on Addition to DJIA

1 nov. 2024, 22:13 UTC

Principalele dinamici ale pieței

Chewy Up 5% on S&P MidCap 400 Inclusion

1 nov. 2024, 21:39 UTC

Câștiguri

Insurance Company Chubb Projects Up to $300 Million Pre-Tax Loss on Hurricane

2 nov. 2024, 13:53 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- Update

2 nov. 2024, 13:44 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 13:00 UTC

Câștiguri

China's EV Makers Set Sights on Latin America in Global Expansion -- WSJ

2 nov. 2024, 12:58 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 12:48 UTC

Câștiguri

Achiziții, Fuziuni, Preluări

Warren Buffett's Berkshire Hathaway Slashes Apple Stake Again -- WSJ

2 nov. 2024, 12:32 UTC

Câștiguri

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov. 2024, 12:28 UTC

Achiziții, Fuziuni, Preluări

Berkshire Sold 25% of Its Apple Stock in the Third Quarter -- Barrons.com

2 nov. 2024, 12:17 UTC

Câștiguri

Berkshire Profits Fell 6% in Third Quarter. The Buybacks Are on Pause. -- Barrons.com

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q EPS $18272.00 >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q BNSF Operating Earnings $1.38B >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Berkshire Hathaway Energy Company Operating Earnings $1.63B >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Insurance-Underwriting Operating Earnings $750M >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Other Operating Loss $877M >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Insurance-Investment Income Operating Earnings $3.66B >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Net $26.25B >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Other Controlled Businesses Operating Earnings $3.34B >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Non-Controlled Businesses Operating Earnings $199M >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Operating Earnings $10.09B >BRKA

2 nov. 2024, 12:00 UTC

Câștiguri

Berkshire Hathaway 3Q Investment, Derivative Gains $16.16B >BRKA

2 nov. 2024, 09:30 UTC

Top știri

Awful Jobs Report Aside, the Economy Is Still Strong -- Heard on the Street -- WSJ

2 nov. 2024, 08:20 UTC

Market Talk

Câștiguri

Tech, Media & Telecom Roundup: Market Talk

2 nov. 2024, 08:20 UTC

Market Talk

Câștiguri

Auto & Transport Roundup: Market Talk

1 nov. 2024, 22:51 UTC

Câștiguri

Correction to Nvidia to Replace Intel in Dow Jones Industrial Average Article -- WSJ

1 nov. 2024, 22:00 UTC

Top știri

Câștiguri

Nvidia to Replace Intel in Dow Jones Industrial Average. Sherwin-Williams Also Joins. -- WSJ

1 nov. 2024, 21:29 UTC

Top știri

Câștiguri

Exxon and Chevron Feel Brunt of Cheaper Oil -- 2nd Update

1 nov. 2024, 21:24 UTC

Câștiguri

Insurance Company Chubb Projects Up to $300M Pre-Tax Loss on Hurricane

Comparație

Modificare preț

MacroGenics Inc Așteptări

Obiectiv de preț

By TipRanks

84.5% sus

Prognoză pe 12 luni

Medie 7.14 USD 84.5%

Maxim 14 USD

Minim 4 USD

În baza a 10 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMacroGenics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

10 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 10 analiști care au acordat evaluări ale acțiunilor MacroGenics Inc - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

3.34 / 3.9Suport & Rezistență

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

346 / 389 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre MacroGenics Inc

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.